Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial - I2BC Accéder directement au contenu
Article Dans Une Revue Journal of Thoracic Oncology Année : 2021

Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial

Xavier Veaute
Didier Busso
Stéphane Marcand
Hidenobu Ishii
  • Fonction : Auteur
Filippo de Marinis
  • Fonction : Auteur
Aleksandra Szczesna
  • Fonction : Auteur
Andreas Polychronis
  • Fonction : Auteur
Ruchan Uslu
  • Fonction : Auteur
Osvaldo Arén Frontera
  • Fonction : Auteur
Huiling Xiong
  • Fonction : Auteur

Résumé

Abstract Specific proteins present at telomeres ensure chromosome end stability, in large part through unknown mechanisms. In this work, we address how the Saccharomyces cerevisiae ORC-related Rif2 protein protects telomere. We show that the small N-terminal Rif2 BAT motif ( B locks A ddition of T elomeres) previously known to limit telomere elongation and Tel1 activity is also sufficient to block NHEJ and 5’ end resection. The BAT motif inhibits the ability of the Mre11-Rad50-Xrs2 complex (MRX) to capture DNA ends. It acts through a direct contact with Rad50 ATP-binding Head domains. Through genetic approaches guided by structural predictions, we identify residues at the surface of Rad50 that are essential for the interaction with Rif2 and its inhibition. Finally, a docking model predicts how BAT binding could specifically destabilise the DNA-bound state of the MRX complex. From these results, we propose that when an MRX complex approaches a telomere, the Rif2 BAT motif binds MRX Head in its ATP-bound resting state. This antagonises MRX transition to its DNA-bound state, and favours a rapid return to the ATP-bound state. Unable to stably capture the telomere end, the MRX complex cannot proceed with the subsequent steps of NHEJ, Tel1-activation and 5’ resection.
Fichier principal
Vignette du fichier
S1556086421018323.pdf (970.31 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03627353 , version 1 (02-08-2023)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Florian Roisné-Hamelin, Sabrina Pobiega, Kévin Jézéquel, Simona Miron, Jordane Dépagne, et al.. Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. Journal of Thoracic Oncology, 2021, 16 (8), pp.1369-1378. ⟨10.1016/j.jtho.2021.03.009⟩. ⟨hal-03627353⟩
44 Consultations
17 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More